Medico Remedies share price
NSE: MEDICOBSE: 540937Pharmaceuticals & BiotechnologySmall Cap
Medico Remedies Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2018 on BSE, May 2022 on NSE
Last close ₹18.98down ₹0.24 (1.25%)BSE ₹19.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹19.22.
29 Oct: open ₹19.59, high ₹19.59, low ₹18.80
52-week range of traded prices to 29 Oct 2026
₹18.80Low, 28 Oct 2026₹56.88High, 24 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹158 Cr2,034th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.40
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,56,00480.6% delivered
Results
Standalone; ₹ crore.Medico Remedies quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +50.0%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +33.7%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹69 Crup 22.17%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹2.52 Crdown 57.01%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 3.6%
Revenue by quarter
Peak revenue ₹69 Cr, quarter to Jun 2026; lowest ₹38 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.3 | 39.5 | 41.3 | 38.3 | 52.6 | 58.7 | 56.8 | 69.4 |
| Net profit | 1.6 | 2.6 | 4.3 | 1.8 | 2.6 | 2.9 | 5.9 | 2.5 |
| Net margin | 3.9% | 6.6% | 10.5% | 4.8% | 4.9% | 4.9% | 10.3% | 3.6% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹206 Crup 36.73%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹13 Crup 29.94%
- Net margin
- 6.4%
Revenue by year
Peak revenue ₹206 Cr, year to Mar 2026; lowest ₹61 Cr, year to Mar 2018
Net profit by year, a loss in red
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61 | 98 | 89 | 122 | 121 | 140 | 145 | 151 | 206 |
| Net profit | 1 | 2 | 2 | 3 | 5 | 7 | 8 | 10 | 13 |
| Net margin | 2.0% | 1.6% | 1.8% | 2.1% | 4.0% | 5.2% | 5.7% | 6.7% | 6.4% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, manufacturer and exporter of pharmaceutical formulations, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Medico Remedies PE ratio and valuation
Price to earnings
At or below today's level on 0.1% of 1,019 trading days over the last 5 years.
LowestHighest
Its median42.93Industry median28.38
Price to book
At or below today's level on 0.1% of 1,012 trading days over the last 5 years.
LowestHighest
Its median6.65Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −36.5% | +29.5% | −50.9% | 0.0% |
| 3 years | −24.1% | +22.0% | −37.8% | 0.0% |
Longer windows are left empty: a corporate action or price step on 2021-11-17 that cannot be sized sits inside this window.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Medico Remedies insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 1 pledge filing of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Medico Remedies competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Medico Remedies in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Oxygenta PharmaceuticalOXYGENTAPH | 177 | – | – | +20.6% | – | – | −15.1% | 0.00% |
 Asston PharmaceuticalsAPL | 165 | 318.39 | – | – | – | 1.3% | −2.0% | 0.00% |
 Gujarat Inject (Kerala)GUJINJEC | 164 | 54.93 | 13.89 | +151.6% | +209.0% | 27.4% | 32.9% | 0.00% |
 Smruthi OrganicsSMRUTHIORG | 163 | 22.05 | 2.22 | −4.6% | +118.2% | 10.2% | 14.8% | 1.05% |
 Par Drugs and ChemicalsPAR | 149 | 11.43 | 1.24 | +9.4% | +34.1% | 11.5% | 12.3% | 0.00% |
 Curis LifesciencesCURIS | 146 | 21.16 | 3.09 | – | – | 14.6% | 15.1% | 0.00% |
 Auro LaboratoriesAUROLAB | 145 | 30.97 | 3.13 | +125.5% | – | 10.5% | 8.8% | 0.00% |
 Kimia BiosciencesKIMIABL | 144 | 20.05 | 8.13 | −6.7% | −18.2% | 51.9% | 19.1% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Medico Remedies announcements
Sep 2026
29 Sep · Legal
The exchange asked on 29 Sep 2026
22 Sep · Meeting
Aug 2026
29 Aug · General Updates
29 Aug · Meeting
17 Aug · Legal
Medico Remedies share price by year
Each calendar year to 2025.Medico Remedies share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 50.60 | −7.9% | 78.08 | 38.19 |
| 2024 | 54.95 | −34.4% | 90.65 | 35.65 |
| 2023 | 83.80 | +28.6% | 96.70 | 60.89 |
| 2022BSE close | 65.17 | +181.6% | 65.88 | 15.44 |
| 2021BSE close | 23.14 | – | 29.87 | 23.14 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 17 Nov 2021.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 20.69 | 20.69 | 18.80 | 19.22 | 19.47 | 2,29,331 | 70.4% |
| 27 Oct 2026 | 20.24 | 20.57 | 20.09 | 20.42 | 20.38 | 36,759 | 71.3% |
| 26 Oct 2026 | 20.28 | 20.28 | 19.68 | 20.08 | 19.98 | 1,05,127 | 59.2% |
| 23 Oct 2026 | 20.55 | 20.64 | 19.11 | 19.90 | 19.76 | 1,57,783 | 51.0% |
| 22 Oct 2026 | 20.97 | 20.97 | 20.30 | 20.50 | 20.59 | 64,951 | 55.7% |
| 21 Oct 2026 | 21.80 | 22.00 | 20.62 | 20.78 | 21.02 | 1,36,099 | 66.6% |
| 19 Oct 2026 | 22.04 | 22.45 | 21.14 | 21.43 | 21.47 | 2,02,900 | 79.0% |
| 16 Oct 2026 | 22.30 | 22.30 | 21.75 | 22.03 | 21.97 | 1,54,707 | 74.2% |
| 15 Oct 2026 | 22.20 | 22.45 | 21.80 | 21.91 | 22.15 | 1,54,699 | 59.8% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 25 Sep 2026 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 27 Feb 2025 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 16 Mar 2023 | Split | 0.2000 | Each share became 5. |
| 17 Nov 2021 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- MEDICO
- BSE code
- 540937
- ISIN
- INE630Y01024
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.medicoremedies.com
- CIN
- L24230MH1994PLC077187
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1994
- Registered office
- 1105/1106, Hubtown Solaris, 11th Floor, Opp. Telli Galli, N S Phadke Marg, Andheri East, Mumbai 400069, Maharashtra
- Share registrar
- Cameo Corporate Services Ltd
- Keeps the register of shareholders and handles transfers and dividend payments